Therefore, targeting PTPN2 may not only enhance the antigen‐specific activation and function of CAR T cells, but also limit “on‐target off‐tumour” toxicities by driving the homing of CXCR3‐expressing CAR T cells to CXCL9/10/11‐expressing tumours. Here, CXCL9 is linked to neoplasm.